

DATAR CANCER GENETICS PARTNERS WITH THE CANCER SCREENING TRUST TO OFFER BLOOD-BASED TEST FOR EARLY CANCER DETECTION

LONDON, UNITED KINGDOM, June 13, 2022 /EINPresswire.com/ -- [Datar Cancer Genetics](#) has announced its partnership with U.K. based The Cancer Screening Trust to offer its innovative, blood-based, cancer screening [Trucheck](#) solution. Datar Cancer Genetics has been at the forefront of developing greater insight into the cancer ecosystem and offering its innovative oncology focused services to clinicians and patients globally.

"Our collaboration with The Cancer Screening Trust will allow individuals to avail our cancer screening solutions serviced by our UK lab. Our passion and commitment is to deliver best-in-class, unparalleled range of blood based diagnostics for clinicians and patients globally", said Dr Vineet Datta, Executive Director, Datar Cancer Genetics. "We are delighted this partnership will offer our highly accurate cancer detection technology to provide more comprehensive cancer screening. Trucheck is a comprehensive, cancer detection solution that can detect over 70 cancers, with a meaningfully unparalleled combination of sensitivity and specificity for early detection of cancers in asymptomatic individuals and localization of the detected cancers to tissue and organ of origin."

"The Cancer Screening Trust is delighted to be in partnership with Datar Cancer Genetics and to be able to offer the Trucheck Intelli blood test to all our clients, as part of our lifetime screening programme. This non-invasive, early detection tool will greatly enhance our Whole Body MRI scan, to offer the best screening package and peace of mind. Datar Cancer Genetics have made significant progress in the liquid biopsy arena and together we will help to diagnose cancer earlier and save lives" said Frank Hogarty, CEO of The Cancer Screening Trust Ltd.



Datar Cancer Genetics UK lab facility



Trucheck is a comprehensive and highly accurate cancer screening solution, that can enable early detection of multiple cancers in asymptomatic individuals”

Dr Vineet Datta

Datar Cancer Genetics is a leading cancer research corporation specializing in non-invasive techniques for better screening, diagnosis, and management of cancer. Datar Cancer Genetics has a College of American Pathologists (CAP), CLIA, ISO15189, ISO9001 and ISO27001 accredited molecular genomic facility at India with a staff strength of over 200, in addition to a state-of-the-art lab facility in the United Kingdom. Our team of scientists, clinicians, advisors and experts, based out of the United Kingdom, U.S.A., Germany and India, help advance our

innovative technologies for better cancer management.

About The Cancer Screening Trust

The Cancer Screening Trust Ltd is a non profit organisation set up to offer a lifetime screening programme to individuals. The company offers an initial consultation, a blood test and a Whole Body MRI scan to gain the fullest picture of a patient’s health, so as to detect any abnormalities at the earliest opportunity. Their aim is to help clients take a proactive stance in their health management and to play a part in the drive to reduce cancer mortality.

CONTACT: Dr Vineet Datta - drvineetdatta@datarpgx.com

Website www.uk.datarpgx.com

CONTACT : Frank Hogarty - frank@thecancerscreeningtrust.co.uk

Website www.thecancerscreeningtrust.co.uk

Dr Vineet Datta

Datar Cancer Genetics

drvineetdatta@datarpgx.com

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/576188701>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.